title: Sweet buttermilk intake reduces colonisation and translocation of Listeria monocytogenes in rats by inhibiting mucosal pathogen adherence.
abstract: The bovine milk fat globule membrane (MFGM) contains several antimicrobial components with proven efficacy in vitro, but in vivo evidence is scarce. The present study was performed to determine the efficacy of the bovine MFGM in vivo. Rats were fed diets based on bovine skimmed milk powder (low in MFGM) or bovine sweet buttermilk powder (high in MFGM). After dietary adaptation, rats were orally infected with Salmonella enteritidis or Listeria monocytogenes. Whereas sweet buttermilk powder did not protect rats against infection with S. enteritidis, it protected against L. monocytogenes, as shown by a lower colonisation and translocation of this pathogen. Protection coincided with higher listericidal capacity of gastric and caecal contents. The digestion products of phosphoglycerides and sphingomyelin are bactericidal in vitro. To study their role, rats were fed diets containing either 0·1 % phosphatidylcholine or sphingomyelin, or a control diet. After dietary adaptation, rats were infected with L. monocytogenes. Since Listeria colonisation was not affected by these diets, phosphoglycerides and sphingomyelin are not involved in the protective effect of sweet buttermilk. Additional in vitro experiments were performed to further explore the mechanism of the beneficial effects of sweet buttermilk. Inhibition of the adherence of L. monocytogenes to the intestinal mucosa is the most likely explanation, since sweet buttermilk powder inhibited the binding of L. monocytogenes in both a haemagglutination assay and a Caco-2 cell adherence assay. In conclusion, sweet buttermilk powder, which is rich in MFGM, protects against L. monocytogenes infection in rats, probably by preventing adherence of this pathogen to the intestinal mucosa.
authors.affiliation: Health Division, NIZO Food Research, PO Box 20, 6710 BA Ede, The Netherlands. corinne.sprong@nizo.nl
authors.forename: R Corinne
authors.initials: RC
authors.lastname: Sprong
authors.forename: Marco F E
authors.initials: MF
authors.lastname: Hulstein
authors.forename: Tim T
authors.initials: TT
authors.lastname: Lambers
authors.forename: Roelof
authors.initials: R
authors.lastname: van der Meer
mesh_terms: D000818:Animals; D000890:Anti-Infective Agents / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D001422:Bacterial Adhesion; D018988:Bacterial Translocation; D018938:Caco-2 Cells; D002417:Cattle; D043302:Cultured Milk Products; D005243:Feces / Q000382:microbiology; D057141:Food, Preserved; D005766:Gastrointestinal Contents / Q000737:chemistry / Q000382:microbiology; D020404:Glycerophospholipids / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D006017:Glycolipids / Q000627:therapeutic use; D006023:Glycoproteins / Q000627:therapeutic use; D006801:Humans; D007413:Intestinal Mucosa / Q000378:metabolism / Q000382:microbiology*; D066292:Lipid Droplets; D008089:Listeria monocytogenes / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification / Q000502:physiology*; D008088:Listeriosis / Q000517:prevention & control*; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012477:Salmonella enteritidis / Q000254:growth & development / Q000302:isolation & purification / Q000502:physiology; D013047:Specific Pathogen-Free Organisms; D013109:Sphingomyelins / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D020404:Glycerophospholipids; D006017:Glycolipids; D006023:Glycoproteins; D013109:Sphingomyelins; C110367:milk fat globule